Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acro Biomedical CoACBM 12-1 Month Momentum % is 3614.29% as of Aug. 30, 2026. The stock has 2 warning signs investors should review. Among 400 Diversified Financial Services companies, Acro Biomedical Co ranks better than 99.75% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-30), Acro Biomedical Co's 12-1 Month Momentum % is 3614.29%.
The industry rank for Acro Biomedical Co's 12-1 Month Momentum % or its related term are showing as below:
ACBM's 12-1 Month Momentum % is ranked better than 99.75% of 400
companies
in the Diversified Financial Services industry
Industry Median: 2.42
vs ACBM: 3614.29
Acro Biomedical Co (OTCPK:ACBM) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Acro Biomedical Co 12-1 Month Momentum % Related Terms
ACBM vs RNGC, EEGI, AGIN: 12-1 Month Momentum % Comparison
For the Shell Companies subindustry, Acro Biomedical Co's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acro Biomedical Co 12-1 Month Momentum % vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Acro Biomedical Co's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Acro Biomedical Co's 12-1 Month Momentum % falls into.
Acro Biomedical Co (OTCPK:ACBM) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of 3614.29% mean?
Acro Biomedical Co (ACBM) has a 12-1 Month Momentum % of 3614.29% as of Aug. 30, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Acro Biomedical Co and its competitors. According to the industry distribution chart, Acro Biomedical Co ranks #1 out of 400 companies in the Diversified Financial Services industry, placing it in the top 0.2%.
Is Acro Biomedical Co's 12-1 Month Momentum % too high?
Acro Biomedical Co's current 12-1 Month Momentum % is 3614.29%. The Diversified Financial Services industry median 12-1 Month Momentum % is 2.42. Acro Biomedical Co's value of 3614.29% is 149250.8% above this industry median. Based on the distribution chart, Acro Biomedical Co ranks #1 out of 400 companies in the Diversified Financial Services industry, which is in the top quartile — a strong position relative to peers.
How does Acro Biomedical Co's 12-1 Month Momentum % compare to RNGC and EEGI?
According to the Diversified Financial Services industry distribution chart, Acro Biomedical Co ranks #1 out of 400 companies for 12-1 Month Momentum %. This places Acro Biomedical Co in the top 0% of its industry — outperforming the majority of peers. The industry median 12-1 Month Momentum % is 2.42. Acro Biomedical Co's value of 3614.29% is 149250.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Diversified Financial Services company?
The median 12-1 Month Momentum % among Diversified Financial Services companies is 2.42, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a 12-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acro Biomedical Co's current 12-1 Month Momentum % of 3614.29% is 149250.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Acro Biomedical Co and its competitors. For the Diversified Financial Services industry, the median 12-1 Month Momentum % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acro Biomedical Co's current 12-1 Month Momentum % is 3614.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acro Biomedical Co stock overvalued right now?
Acro Biomedical Co (ACBM) has a current 12-1 Month Momentum % of 3614.29%. The current 12-1 Month Momentum % is 3614.29% and 149250.8% above the Diversified Financial Services industry median of 2.42. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Acro Biomedical Co (ACBM), the current 12-1 Month Momentum % is 3614.29% as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACBM has been successfully added to your 
